文献速递结核与非结核分枝杆菌

利福平高剂量根除持续菌可缩短结核治疗并防复发

Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

该研究利用Cornell小鼠模型,评估提高利福平剂量联合异烟肼和吡嗪酰胺对活跃生长及持续存活结核分枝杆菌的杀菌效果及复发率。结果显示,利福平≥30 mg/kg可完全防止复发,并在8-11周内实现器官无菌,而标准剂量10 mg/kg治疗14周仍未达无菌。

要点

  • 利福平≥30 mg/kg可根除持续性结核菌并完全防止复发。
  • 标准剂量10 mg/kg治疗14周未达器官无菌,复发率86%。
  • 高剂量利福平可将达到器官无菌的时间缩短至8-11周。

核心结论

  • 在小鼠结核治疗中,利福平30 mg/kg足以根除持续性结核分枝杆菌,缩短治疗时间且不复发。

研究设计与样本

  • 采用Cornell小鼠模型,测试提高利福平剂量联合异烟肼和吡嗪酰胺的疗效,评估对活跃生长和持续存活菌的杀菌及复发率。

主要发现

  • 增加利福平剂量联合异烟肼和吡嗪酰胺导致剂量依赖性更快的细菌清除。
  • 标准剂量利福平10 mg/kg治疗14周未达到器官无菌。
  • 较高剂量利福平在8-11周内达到器官无菌。
  • 标准方案治疗14周的小鼠复发率为86%,而利福平剂量≥30 mg/kg完全防止复发。

关键数值与推荐

  • 利福平标准剂量为10 mg/kg,治疗14周未达器官无菌。
  • 利福平剂量≥30 mg/kg完全防止复发。
  • 高剂量利福平达到器官无菌的时间为8-11周。

临床怎么用

  • 提示临床可考虑提高利福平剂量至≥30 mg/kg以根除持续菌、缩短疗程并降低复发,但需进一步人体研究验证。

局限性

  • 研究基于小鼠模型,结果需在人体临床试验中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Although high-dose rifampicin holds promise for improving tuberculosis disease control by eradication of persistent bacteria, the optimal dose of rifampicin that kills persistent bacteria and shortens the treatment duration is unknown. METHODS: The Cornell mouse model was used to test the efficacy of rifampicin at elevated doses combined with isoniazid and pyrazinamide to kill actively growing and persistent bacilli and to measure relapse rate. Persistent bacteria were evaluated using Mycobacterium tuberculosis culture supernatant containing resuscitation-promoting factors. Pharmacokinetic parameters and dose-dependent activity for cultivable and persistent bacilli were determined. RESULTS: Increasing doses of rifampicin in combination with isoniazid and pyrazinamide resulted in dose-dependent faster bacterial clearance. Evaluated both on solid media and in culture filtrate containing resuscitation-promoting factors, a regimen containing a standard dose of rifampicin at 10 mg/kg over 14 weeks failed to achieve organ sterility. In contrast, higher doses of rifampicin achieved organ sterility in a much shorter time of 8-11 weeks. Disease relapse, which occurred in 86% of mice treated with the standard regimen for 14 weeks, was completely prevented by rifampicin doses of ≥ 30 mg/kg. CONCLUSIONS: In the treatment of murine tuberculosis, a rifampicin dose of 30 mg/kg was sufficient to eradicate persistent M. tuberculosis, allowing shorter treatment duration without disease relapse.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Liu Y, Pertinez H, Ortega-Muro F, et al. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. J Antimicrob Chemother. 2018. PMID: 29244108. doi:10.1093/jac/dkx467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。